Szoor A - Search Results

1

CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.

Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. Bonifant CL, et al. Among authors: szoor a. Mol Ther. 2016 Sep 29;24(9):1615-26. doi: 10.1038/mt.2016.116. Epub 2016 Jun 6. Mol Ther. 2016. PMID: 27401038 Free PMC article.

2

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies.

Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, Szoor A, Bonifant CL, Gerken C, Cooper LJ, Song XT, Gottschalk S. Velasquez MP, et al. Among authors: szoor a. Sci Rep. 2016 Jun 3;6:27130. doi: 10.1038/srep27130. Sci Rep. 2016. PMID: 27255991 Free PMC article.

3

CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells.

Velasquez MP, Szoor A, Vaidya A, Thakkar A, Nguyen P, Wu MF, Liu H, Gottschalk S. Velasquez MP, et al. Among authors: szoor a. Cancer Immunol Res. 2017 Oct;5(10):860-870. doi: 10.1158/2326-6066.CIR-17-0171. Epub 2017 Aug 18. Cancer Immunol Res. 2017. PMID: 28821531 Free PMC article.

4

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.

Szoor A, Vaidya A, Velasquez MP, Mei Z, Galvan DL, Torres D, Gee A, Heczey A, Gottschalk S. Szoor A, et al. Mol Ther Oncolytics. 2017 Jul 28;6:69-79. doi: 10.1016/j.omto.2017.07.002. eCollection 2017 Sep 15. Mol Ther Oncolytics. 2017. PMID: 28856237 Free PMC article.

5

Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models.

Csaplár M, Szöllősi J, Gottschalk S, Vereb G, Szöőr Á. Csaplár M, et al. Among authors: szoor a. Cancers (Basel). 2021 Aug 26;13(17):4301. doi: 10.3390/cancers13174301. Cancers (Basel). 2021. PMID: 34503109 Free PMC article.

6

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts.

Tóth G, Szöllősi J, Abken H, Vereb G, Szöőr Á. Tóth G, et al. Among authors: szoor a. Int J Mol Sci. 2020 Feb 4;21(3):1039. doi: 10.3390/ijms21031039. Int J Mol Sci. 2020. PMID: 32033208 Free PMC article.

7

TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.

Govers C, Sebestyén Z, Roszik J, van Brakel M, Berrevoets C, Szöőr Á, Panoutsopoulou K, Broertjes M, Van T, Vereb G, Szöllősi J, Debets R. Govers C, et al. Among authors: szoor a. J Immunol. 2014 Nov 15;193(10):5315-26. doi: 10.4049/jimmunol.1302074. Epub 2014 Oct 15. J Immunol. 2014. PMID: 25320284

8

Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.

Szöőr Á, Tóth G, Zsebik B, Szabó V, Eshhar Z, Abken H, Vereb G. Szöőr Á, et al. Cancer Lett. 2020 Aug 1;484:1-8. doi: 10.1016/j.canlet.2020.04.008. Epub 2020 Apr 11. Cancer Lett. 2020. PMID: 32289441 Free article.

9

From antibodies to living drugs: Quo vadis cancer immunotherapy?

Szöőr Á, Szöllősi J, Vereb G. Szöőr Á, et al. Biol Futur. 2021 Mar;72(1):85-99. doi: 10.1007/s42977-021-00072-6. Epub 2021 Feb 1. Biol Futur. 2021. PMID: 34554498 Review.

10

Rafts and the battleships of defense: the multifaceted microdomains for positive and negative signals in immune cells.

Szöor A, Szöllosi J, Vereb G. Szöor A, et al. Immunol Lett. 2010 May 4;130(1-2):2-12. doi: 10.1016/j.imlet.2009.12.016. Epub 2009 Dec 22. Immunol Lett. 2010. PMID: 20026358 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters